TELFORD: A groundbreaking £1 million research initiative to revolutionize colorectal cancer diagnosis has launched at the Community Diagnostic Centre (CDC) in Telford. The TRIOMIC study aims to reduce waiting times, alleviate patient anxiety, and transform the traditional diagnostic pathway for colorectal cancer.
This pioneering trial introduces a new, minimally invasive test designed to replace the need for traditional colonoscopies. Administered at the CDC in Hollinswood House, Stafford Park, the test leverages cutting-edge technology to collect rectal mucus samples using the Oricol device. These samples are analyzed in laboratories to detect abnormal cells linked to cancer and significant polyps.
The year-long study will involve approximately 6,000 symptomatic patients referred under the Colorectal Urgent Suspected Cancer pathway at The Shrewsbury and Telford Hospital NHS Trust (SaTH). If successful, the new test could provide eight out of ten patients with a cancer-free diagnosis within five days, eliminating the need for the 45-minute colonoscopy procedure that typically requires bowel preparation and hospital visits.
SaTH has partnered with Origin Sciences to develop this innovative diagnostic pathway, with the company funding staff and infrastructure costs. The CDC has added three clinic rooms and recruited 14 new staff members to support the trial.
Jon Lacy-Colson, consultant colorectal surgeon and chief investigator for the study, emphasized the trial's significance, saying, “This is an exciting opportunity for the Trust to be at the forefront of a major advancement in colorectal cancer diagnostics. By relocating the pathway to the CDC, we’re improving accessibility and care delivery while reducing hospital pressure.”
Dr. John Jones, SaTH’s medical director, highlighted the potential impact of the test. “If successful, this trial could redefine how colorectal cancer is diagnosed nationwide. Patients will receive quicker diagnoses or reassurances, and the Trust will avoid unnecessary tests, improving efficiency and outcomes,” he stated.
Colorectal cancer affects 42,000 individuals annually in the UK, with SaTH managing around 350 cases each year. Current diagnostic pathways see more than 5,000 patients undergo colonoscopies annually, costing the Trust between £3-5 million. The TRIOMIC study aims to optimize resource use while maintaining the highest standards of patient care.